Document Detail


Responsiveness of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis.
MedLine Citation:
PMID:  18625628     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The comprehensive International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis (RA) is a selection of 96 categories from the ICF, representing relevant aspects in the functioning of patients with RA. OBJECTIVES: To study the responsiveness of the ICF Core Set for RA in rheumatological practice. METHODS: A total of 46 patients with RA (72% women, mean (SD) age 53.6 (12.6) years, disease duration 6.3 (8.0) years) were interviewed at baseline and again after 6 months treatment with a disease-modifying antirheumatic drug (DMARD), applying the ICF Core Set for RA with qualifiers for problems on a modified three-point scale (no problem, mild/moderate, severe/complete). Patient-reported outcomes included Modified Health Assessment Questionnaire (MHAQ) and Short-Form 36 (SF-36) health survey, and disease activity was calculated. Responsiveness was measured as change in qualifiers in ICF categories, and was also compared with change in patient-reported outcomes. RESULTS: After 6 months of DMARD treatment, improvement by at least one qualifier was seen in 20% of patients (averaged across all ICF categories), 71% experienced no change and 9% experienced worsening symptoms. Findings were similar across the different aspects of functioning. Mainly moderate effect sizes were seen for 6-month changes in the ICF Core Set for RA, especially in patients with improved health status, with similar effect size for disease activity. The components in the ICF Core Set for RA were only weakly associated with patient-reported outcomes and disease activity. CONCLUSIONS: The ICF Core Set for RA demonstrated moderate responsiveness in this real-life setting of patients where minor changes occurred during treatment with DMARDs.
Authors:
T Uhlig; R Moe; S Reinsberg; T K Kvien; A Cieza; G Stucki
Related Documents :
8608678 - Prevalence of metacarpal osteopenia in young rheumatoid arthritis patients.
11114278 - Release of cartilage and bone macromolecules into synovial fluid: differences between p...
24108928 - Grey matter and csf amyloid in early non-demented parkinson's disease: the incidence of...
14730598 - Prognostic markers of radiographic progression in early rheumatoid arthritis.
10732828 - The sera from gm1 ganglioside antibody positive patients with guillain-barré syndrome o...
1154478 - Atheromatous emboli to the lumbosacral spinal cord.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-07-14
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  68     ISSN:  1468-2060     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-05-13     Completed Date:  2009-06-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  879-84     Citation Subset:  IM    
Affiliation:
National Resource Center for Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. till.uhlig@diakonsyk.no
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Activities of Daily Living
Adult
Aged
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Disability Evaluation*
Female
Follow-Up Studies
Health Status Indicators
Humans
Male
Middle Aged
Prospective Studies
Questionnaires
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antirheumatic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus.
Next Document:  Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remissi...